1. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions
- Author
-
Dominic J. Allocco, Christophe Dubois, Gregg W. Stone, Paul S. Teirstein, Joseph Dens, Robert L. Feldman, Tommy C. Lee, Vincent J. Pompili, Shigeru Saito, Keith D. Dawkins, A. Charles Rabinowitz, Ian T Meredith, Louis Cannon, and Michael R. Mooney
- Subjects
Target lesion ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,Stent ,General Medicine ,medicine.disease ,Surgery ,Lesion ,Coronary artery disease ,Cohort ,Cardiovascular agent ,medicine ,Radiology, Nuclear Medicine and imaging ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Prospective cohort study - Abstract
Objectives To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies. Background Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation. Methods The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≥2.25 mm to 24 to ≤34 mm long in vessels ≥2.50 to ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions. Results One-year TLF rates with the PtCr-EES were significantly (P
- Published
- 2014
- Full Text
- View/download PDF